Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with over 1 billion sufferers, announces completion and initial validation of a new RefluxStop® U.S. production tool as Implantica prepares for quickly increasing demand from the U.S. and markets worldwide, pending FDA approval.

Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the second quarter will be published at 8:00 a.m. CEST on the same day.

Implantica AG (publ), a leading medtech company pioneering advanced implantable medical technologies, today announced the second peer-reviewed publication of the remarkable 5-year outcomes from its CE mark clinical study of RefluxStop®, a revolutionary device for the treatment of acid reflux—a condition affecting over 1 billion people worldwide.

Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop’s extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy (https://link.springer.com/article/10.1007/s00464-025-11818-x), an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery).

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module.

Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop™, a treatment field with 1 billion sufferers, announces the successful first UK National Users Meeting bringing together 21 top anti-reflux experts in UK last week. Surgeons exchanged their real-world experiences and delved into the positive National Institute for Health and Care Excellence (NICE) recommendations on using RefluxStop in NHS hospitals, opening a vast opportunity for RefluxStop procedures in patients with poor motility, representing up to 40-50%[1] of the acid reflux (GERD/GORD) sufferers.

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the publication of a new independent real-world study (https://pubmed.ncbi.nlm.nih.gov/40317294/) from Switzerland demonstrating RefluxStop™’s consistent long-term outcomes irrespective of large or small hiatal hernia size before surgery, proving it to be a favorable option for patients also with large hernia.

Implantica AG (publ.), providing the unique device RefluxStop™ for the treatment of acid reflux, announces that the world-renowned National Institute for Healthcare Excellence (NICE (https://www.nice.org.uk/)) payer advisory agency for NHS public hospitals in the UK has published positive Interventional Procedures Guidance (IPG) recommendations on the RefluxStop™ procedure, wherein GORD/GERD patients with Ineffective Oesophageal Motility (IOM/IEM) are allowed to be operated with RefluxStop procedure in the public healthcare system, following its guidelines and special arrangements.

Implantica AG (publ.) reports successful pre-launch activities in the U.S., pending FDA approval, with European real-world clinical evidence generating much interest from U.S. surgeons.